Syndax Announces Participation in March Investor Conferences

WALTHAM, Mass., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that Michael A. Metzger, Chief Executive Officer of Syndax, as well as members of the Syndax management team, will participate in the following upcoming investor conferences:

• TD Cowen 45th Annual Health Care Conference in Boston, MA, with a fireside chat on Tuesday, March 4, 2025, at 3:10 p.m. ET
• Barclays 27th Annual Global Healthcare Conference in Miami Beach, FL, with a fireside chat on Thursday, March 13, 2025, at 8:30 a.m. ET

A live webcast of the fireside chats will be available in the Investor section of the Company's website at www.syndax.com, where a replay will also be available for a limited time.

About Syndax

Syndax Pharmaceuticals is a commercial-stage biopharmaceutical company developing an innovative pipeline of cancer therapies. Highlights of the Company's pipeline include Revuforj^® (revumenib), an FDA-approved menin inhibitor, and Niktimvo™ (axatilimab-csfr), an FDA-approved monoclonal antibody that blocks the colony stimulating factor 1 (CSF-1) receptor. Fueled by our commitment to reimagining cancer care, Syndax is working to unlock the full potential of its pipeline and is conducting several clinical trials across the continuum of treatment. For more information, please visit www.syndax.com/ or follow the Company on X and LinkedIn.

Syndax Contacts

Sharon Klahre
Syndax Pharmaceuticals, Inc.
[email protected]
Tel 781.684.9827

SNDX-G

You May Also Be Interested In

• Breeze Acquisition Corp. II Announces Receipt of Notice from Nasdaq Regarding Late Filing of Quarterly Reports on Form 10-Q
• Orange County Bancorp, Inc. Declares Cash Dividend
• United Fire Group, Inc. declares quarterly cash dividend of $0.20 per share and announces new board appointment